Clinical Trials Browser

Phase 1/2 × Withdrawn × C188-9 compound × Clear all

NCT05668949 2025-12-17

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1/2 Withdrawn

Squamous Cell Carcinoma of Head and Neck